Literature DB >> 19455303

Glucose metabolism and the risk of Alzheimer's disease and dementia: a population-based 12 year follow-up study in 71-year-old men.

E Rönnemaa1, B Zethelius, J Sundelöf, J Sundström, M Degerman-Gunnarsson, L Lannfelt, C Berne, L Kilander.   

Abstract

AIMS/HYPOTHESIS: Accumulating evidence suggests that diabetes increases the risk of dementia, but few studies have addressed possible mechanisms underlying this relationship. The aim of our study was to investigate the longitudinal association of glucose metabolism, insulin secretion and insulin action with the development of Alzheimer's disease and vascular dementia.
METHODS: The Uppsala Longitudinal Study of Adult Men is an ongoing observational study in Sweden in which 1,125 men aged 71 years and free from dementia underwent an OGTT and a euglycaemic insulin clamp between 1990 and 1995. During a median follow-up of 12 years, 257 persons developed dementia or cognitive impairment, of whom 81 had Alzheimer's disease and 26 vascular dementia. Associations were analysed with the Cox proportional hazards method.
RESULTS: Low early insulin response to oral glucose challenge, but not low insulin sensitivity, was associated with a higher risk of Alzheimer's disease (HR for 1 SD decrease 1.32; 95% CI 1.02, 1.69) after adjustment for diabetes, blood pressure, body mass index, cholesterol, smoking and educational level. Low insulin sensitivity was associated with a higher risk of vascular dementia (HR for 1 SD decrease 1.55; 95% CI 1.02, 2.35), but not after multiple adjustments. Diabetes increased the risk of any dementia and cognitive impairment by 63%. CONCLUSIONS/
INTERPRETATION: In this community-based study, low early insulin response was associated with increased risk of subsequent Alzheimer's disease, whereas low insulin sensitivity was not. Vascular dementia was not related to early insulin response. We suggest that glucometabolic disturbances are linked differentially to the pathogenesis of these two main dementia subtypes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19455303     DOI: 10.1007/s00125-009-1393-9

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  31 in total

1.  Association of metabolic syndrome with Alzheimer disease: a population-based study.

Authors:  M Vanhanen; K Koivisto; L Moilanen; E L Helkala; T Hänninen; H Soininen; K Kervinen; Y A Kesäniemi; M Laakso; J Kuusisto
Journal:  Neurology       Date:  2006-09-12       Impact factor: 9.910

2.  Usefulness of plasma glucose and insulin concentrations in identifying patients with insulin resistance.

Authors:  Cheng-Yang Tuan; Fahim Abbasi; Cindy Lamendola; Tracey McLaughlin; Gerald Reaven
Journal:  Am J Cardiol       Date:  2003-09-01       Impact factor: 2.778

3.  Measuring cognitive function with age: the influence of selection by health and survival.

Authors:  Sjoerd M Euser; Miranda T Schram; Albert Hofman; Rudi G J Westendorp; Monique M B Breteler
Journal:  Epidemiology       Date:  2008-05       Impact factor: 4.822

4.  Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function.

Authors:  S E Kahn; R L Prigeon; D K McCulloch; E J Boyko; R N Bergman; M W Schwartz; J L Neifing; W K Ward; J C Beard; J P Palmer
Journal:  Diabetes       Date:  1993-11       Impact factor: 9.461

5.  Asymptomatic atherosclerosis and insulin resistance.

Authors:  M Laakso; H Sarlund; R Salonen; M Suhonen; K Pyörälä; J T Salonen; P Karhapää
Journal:  Arterioscler Thromb       Date:  1991 Jul-Aug

6.  Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development.

Authors:  C Weyer; P A Tataranni; C Bogardus; R E Pratley
Journal:  Diabetes Care       Date:  2001-01       Impact factor: 19.112

7.  Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study.

Authors:  S Kalmijn; D Foley; L White; C M Burchfiel; J D Curb; H Petrovitch; G W Ross; R J Havlik; L J Launer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-10       Impact factor: 8.311

8.  Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulins.

Authors:  W J Sobey; S F Beer; C A Carrington; P M Clark; B H Frank; I P Gray; S D Luzio; D R Owens; A E Schneider; K Siddle
Journal:  Biochem J       Date:  1989-06-01       Impact factor: 3.857

9.  Impaired insulin secretion increases the risk of Alzheimer disease.

Authors:  E Rönnemaa; B Zethelius; J Sundelöf; J Sundström; M Degerman-Gunnarsson; C Berne; L Lannfelt; L Kilander
Journal:  Neurology       Date:  2008-04-09       Impact factor: 9.910

10.  Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo.

Authors:  Wesley Farris; Stefan Mansourian; Yang Chang; Loren Lindsley; Elizabeth A Eckman; Matthew P Frosch; Christopher B Eckman; Rudolph E Tanzi; Dennis J Selkoe; Suzanne Guenette
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-12       Impact factor: 11.205

View more
  28 in total

Review 1.  Diabetes type II: a risk factor for depression-Parkinson-Alzheimer?

Authors:  Peter Riederer; Jasmin Bartl; Gerd Laux; Edna Grünblatt
Journal:  Neurotox Res       Date:  2010-06-15       Impact factor: 3.911

Review 2.  Obesity, insulin resistance, and Alzheimer's disease.

Authors:  Kerry L Hildreth; Rachael E Van Pelt; Robert S Schwartz
Journal:  Obesity (Silver Spring)       Date:  2012-02-07       Impact factor: 5.002

Review 3.  Food for thought: the role of appetitive peptides in age-related cognitive decline.

Authors:  Jim R Fadel; Corinne G Jolivalt; Lawrence P Reagan
Journal:  Ageing Res Rev       Date:  2013-02-13       Impact factor: 10.895

4.  Insulin metabolism and the risk of Alzheimer disease: the Rotterdam Study.

Authors:  E M C Schrijvers; J C M Witteman; E J G Sijbrands; A Hofman; P J Koudstaal; M M B Breteler
Journal:  Neurology       Date:  2010-11-30       Impact factor: 9.910

5.  The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease.

Authors:  Caitriona M Long-Smith; Sean Manning; Paula L McClean; Meghan F Coakley; Domhnall J O'Halloran; Christian Holscher; Cora O'Neill
Journal:  Neuromolecular Med       Date:  2012-09-21       Impact factor: 3.843

6.  A link between type 2 diabetes and brain function.

Authors:  Christina E Hugenschmidt
Journal:  JAAPA       Date:  2013-12

7.  What is Your Risk of Contracting Alzheimer's Disease? A Telematics Tool Helps you to Predict it.

Authors:  Rodrigo Méndez-Sanz; Isabel de la Torre-Díez; Miguel López-Coronado
Journal:  J Med Syst       Date:  2015-10-29       Impact factor: 4.460

8.  Glucose levels and risk of dementia.

Authors:  Paul K Crane; Rod Walker; Rebecca A Hubbard; Ge Li; David M Nathan; Hui Zheng; Sebastien Haneuse; Suzanne Craft; Thomas J Montine; Steven E Kahn; Wayne McCormick; Susan M McCurry; James D Bowen; Eric B Larson
Journal:  N Engl J Med       Date:  2013-08-08       Impact factor: 91.245

9.  Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.

Authors:  B E de Galan; S Zoungas; J Chalmers; C Anderson; C Dufouil; A Pillai; M Cooper; D E Grobbee; M Hackett; P Hamet; S R Heller; L Lisheng; S MacMahon; G Mancia; B Neal; C Y Pan; A Patel; N Poulter; F Travert; M Woodward
Journal:  Diabetologia       Date:  2009-08-18       Impact factor: 10.122

10.  Glycogen synthase kinase-3 inhibition prevents learning deficits in diabetic mice.

Authors:  Matthew R King; Nicholas J Anderson; Lucie S Guernsey; Corinne G Jolivalt
Journal:  J Neurosci Res       Date:  2013-01-30       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.